雜志介紹

Cancer Immunology Research雜志介紹

《Cancer Immunology Research》是一本以English為主的未開放獲取國際優(yōu)秀期刊，中文名稱癌癥免疫學(xué)研究，本刊主要出版、報道醫(yī)學(xué)-IMMUNOLOGY領(lǐng)域的研究動態(tài)以及在該領(lǐng)域取得的各方面的經(jīng)驗和科研成果，介紹該領(lǐng)域有關(guān)本專業(yè)的最新進(jìn)展，探討行業(yè)發(fā)展的思路和方法，以促進(jìn)學(xué)術(shù)信息交流，提高行業(yè)發(fā)展。該刊已被國際權(quán)威數(shù)據(jù)庫SCIE收錄，為該領(lǐng)域相關(guān)學(xué)科的發(fā)展起到了良好的推動作用，也得到了本專業(yè)人員的廣泛認(rèn)可。該刊最新影響因子為8.1，最新CiteScore 指數(shù)為15.6。

本刊近期中國學(xué)者發(fā)表的論文主要有：

• HRS Regulates Small Extracellular Vesicle PD-L1 Secretion and Is Associated with Anti-PD-1 Treatment Efficacy

  Author: Xiao, Bo -Lin; Wang, Xiao-Le; Xia, Hou-Fu; Wang, Kui-Ming; Chen, Zhuo-Kun; Zhong, Ya-Hua; Jiang, Huan-Gang; Zhou, Fu-Xiang; Wang, Wei; Chen, Gai-Li; Chen, Gang

• Extracellular Vesicle-Packaged circATP2B4 Mediates M2 Macrophage Polarization via miR-532-3p/SREBF1 Axis to Promote Epithelial Ovarian Cancer Metastasis

  Author: Wang, Fang; Niu, Yuequn; Chen, Kelie; Yuan, Xiaoyu; Qin, Yuheng; Zheng, Fang; Cui, Zhenyan; Lu, Weiguo; Wu, Yihua; Xia, Dajing

• HDAC3 Inhibition Promotes Antitumor Immunity by Enhancing CXCL10-Mediated Chemotaxis and Recruiting of Immune Cells

  Author: Li, Lili; Hao, Shumin; Gao, Meiling; Liu, Junxiao; Xu, Xin; Huang, Jianfei; Cheng, Genhong; Yang, Heng

• Suppression of Tumor or Host Intrinsic CMTM6 Drives Antitumor Cytotoxicity in a PD-L1-Independent Manner

  Author: Long, Yiru; Chen, Runqiu; Yu, Xiaolu; Tong, Yongliang; Peng, Xionghua; Li, Fanglin; Hu, Chao; Sun, Jianhua; Gong, Likun

英文介紹

Cancer Immunology Research雜志英文介紹

Cancer Immunology Research publishes outstanding original articles reporting major advances in cancer immunology that span the discipline from basic investigations in host-tumor interactions to developmental therapeutics in model systems, early translational studies in patients, and late-stage clinical trials. The journal disseminates knowledge of immunology to the cancer research community, catalyzing cross-disciplinary work that yields a deeper understanding of the host-tumor relationship, more potent cancer treatments, and improved clinical outcomes.

Papers are stringently reviewed, and specific topics of interest include endogenous antitumor immunity, tumor-promoting inflammation, cancer antigens, vaccines, antibodies, cellular therapy, cytokines, immune regulation, immune suppression, immunomodulatory effects of cancer treatment, emerging technologies, and clinical investigations. The journal's special features include "Masters of Immunology"—primers by leading immunologists—and "Cancer Immunology at the Crossroads"—perspectives that highlight the intersection of immunology with other areas of cancer research and allied disciplines.